Eupraxia hits enrollment target for RESOLVE trial of EP-104GI

Eupraxia Pharmaceuticals has reached the enrollment target for the RESOLVE trial, a mid-stage study testing EP-104GI as a treatment for eosinophilic esophagitis. The company says 120 participants were enrolled in the blinded, placebo-controlled portion, and a statistical team continues periodic reviews of unblinded data to confirm that assumptions about efficacy and sample size remain appropriate.

What happened

Eupraxia announced that it has completed enrollment of 120 patients in the Phase 2b portion of the RESOLVE trial. The trial compares EP-104GI to a placebo in people with eosinophilic esophagitis, a chronic inflammatory condition of the esophagus. The company noted that a statistical team is conducting periodic checks using unblinded data to verify that the study’s design and assumptions about efficacy and the planned sample size remain valid. No results about whether EP-104GI works have been disclosed yet in this update.

Who is affected

Participants in the RESOLVE trial are adults diagnosed with eosinophilic esophagitis who volunteered to be part of a controlled study testing EP-104GI. The news does not indicate effects on patients outside the trial or on the wider population. It also does not alter current medical practice until results are released and reviewed by regulators and the scientific team.

Practical next steps for readers

Read the trial results when the company and investigators publish them, which will indicate whether EP-104GI shows benefit over placebo. If you or a patient consider participation in similar trials, discuss with a physician or a clinical trial coordinator to understand eligibility, potential risks, and how results might affect treatment options. Regulatory decisions will depend on the full data package, including efficacy and safety findings from this and other trial phases.

Limits and questions

The current release covers enrollment status and ongoing data review, not treatment outcomes. Details on efficacy, safety signals, or long-term effects have not been presented. It is also not clear how this study’s results will influence whether EP-104GI becomes approved for eosinophilic esophagitis in different regions. Readers should await the formal results and regulatory assessments for a complete view.

Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.